Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy

Clin Infect Dis. 2023 Jul 26;77(2):242-251. doi: 10.1093/cid/ciad168.

Abstract

Background: In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs).

Methods: Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated.

Results: A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%-100%. For moxifloxacin and rifampicin, the PTAs were 71%-100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%-17%.Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics.

Conclusions: For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis.

Keywords: infective endocarditis; oral antibiotics; pharmacodynamics; pharmacokinetics; target attainment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin
  • Anti-Bacterial Agents / pharmacology
  • Dicloxacillin / therapeutic use
  • Endocarditis* / drug therapy
  • Endocarditis, Bacterial* / drug therapy
  • Endocarditis, Bacterial* / microbiology
  • Humans
  • Linezolid / therapeutic use
  • Microbial Sensitivity Tests
  • Moxifloxacin / therapeutic use
  • Rifampin / therapeutic use

Substances

  • Rifampin
  • Dicloxacillin
  • Linezolid
  • Moxifloxacin
  • Anti-Bacterial Agents
  • Amoxicillin